AbbVie first-in-class makes early appearance
By Megan Brodie 2 years ago | In Industry, Products, Regulatory- 2 years ago
30 September 2024 AbbVie’s antibody drug conjugate (ADC) ELAHERE (mirvetuximab soravtansine) has made its first…
This is subscriber-only content. Please login to continue reading.